Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
- Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund
- Dr Arbat brings over 25 years’ pharma industry experience, including roles in women’s health at Bayer and Organon
- Oriva’s lead asset, ORV-362 – a non-hormonal, disease-modifying, first-in-class therapy for endometriosis – is already in Phase I clinical trials
Barcelona, Spain – 11 June 2026: Oriva Therapeutics (“Oriva”), a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women, today announces the appointment of seasoned biotech entrepreneur Dr Agnès Arbat as Chief Executive Officer.
